Human PD-L1/B7-H1 Antibody | R&D Systems MAB1561 product information

product summary

company name :

R&D Systems

product type :

antibody

product name :

Human PD-L1/B7-H1 Antibody

catalog :

MAB1561

quantity :

100 ug (also 25 ug)

price :

489 USD

clonality :

monoclonal

host :

mouse

conjugate :

nonconjugated

clone name :

130021

reactivity :

human

application :

western blot, ELISA, immunohistochemistry, immunocytochemistry, flow cytometry, immunohistochemistry - paraffin section

more info or order :

R&D Systems product webpage

citations: 24

Reference
Niu Q, Gao J, Zhao K, Chen X, Lin X, Huang C, et al. Fluid nanoporous microinterface enables multiscale-enhanced affinity interaction for tumor-derived extracellular vesicle detection. Proc Natl Acad Sci U S A. 2022;119:e2213236119 pubmed publisher
Hou X, Shi X, Luo J. Efficacy and safety of camrelizumab (a PD-1 inhibitor) combined with chemotherapy as a neoadjuvant regimen in patients with locally advanced non-small cell lung cancer. Oncol Lett. 2022;24:215 pubmed publisher
Labib D, Wang Z, Prakash P, Zimmer M, Smith M, Frazel P, et al. Proteomic Alterations and Novel Markers of Neurotoxic Reactive Astrocytes in Human Induced Pluripotent Stem Cell Models. Front Mol Neurosci. 2022;15:870085 pubmed publisher
Chung Y, Tsai W, Khan P, Ma J, Berek J, Larrick J, et al. FOXO3-dependent suppression of PD-L1 promotes anticancer immune responses via activation of natural killer cells. Am J Cancer Res. 2022;12:1241-1263 pubmed
Chung Y, Khan P, Wang H, Tsai W, Qiao Y, Yu B, et al. Sensitizing tumors to anti-PD-1 therapy by promoting NK and CD8+ T cells via pharmacological activation of FOXO3. J Immunother Cancer. 2021;9: pubmed publisher
Eljaafari A, Pestel J, le Magueresse Battistoni B, Chanon S, Watson J, Robert M, et al. Adipose-Tissue-Derived Mesenchymal Stem Cells Mediate PD-L1 Overexpression in the White Adipose Tissue of Obese Individuals, Resulting in T Cell Dysfunction. Cells. 2021;10: pubmed publisher
Makowska A, Lelabi N, Nothbaum C, Shen L, Busson P, Tran T, et al. Radiotherapy Combined with PD-1 Inhibition Increases NK Cell Cytotoxicity towards Nasopharyngeal Carcinoma Cells. Cells. 2021;10: pubmed publisher
Opzoomer J, Timms J, Blighe K, Mourikis T, Chapuis N, Bekoe R, et al. ImmunoCluster provides a computational framework for the nonspecialist to profile high-dimensional cytometry data. elife. 2021;10: pubmed publisher
Mocan T, Ilies M, Nenu I, Craciun R, Horhat A, Susa R, et al. Serum levels of soluble programmed death-ligand 1 (sPD-L1): A possible biomarker in predicting post-treatment outcomes in patients with early hepatocellular carcinoma. Int Immunopharmacol. 2021;94:107467 pubmed publisher
Acheampong E, Abed A, Morici M, Bowyer S, Amanuel B, Lin W, et al. Tumour PD-L1 Expression in Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis. Cells. 2020;9: pubmed publisher
Cui X, Ma C, Vasudevaraja V, Serrano J, Tong J, Peng Y, et al. Dissecting the immunosuppressive tumor microenvironments in Glioblastoma-on-a-Chip for optimized PD-1 immunotherapy. elife. 2020;9: pubmed publisher
Tian Y, Zhai X, Han A, Zhu H, Yu J. Potential immune escape mechanisms underlying the distinct clinical outcome of immune checkpoint blockades in small cell lung cancer. J Hematol Oncol. 2019;12:67 pubmed publisher
Giampieri R, Piva F, Occhipinti G, Bittoni A, Righetti A, Pagliaretta S, et al. Clinical impact of different exosomes' protein expression in pancreatic ductal carcinoma patients treated with standard first line palliative chemotherapy. PLoS ONE. 2019;14:e0215990 pubmed publisher
Cristiani C, Turdo A, Ventura V, Apuzzo T, Capone M, Madonna G, et al. Accumulation of Circulating CCR7+ Natural Killer Cells Marks Melanoma Evolution and Reveals a CCL19-Dependent Metastatic Pathway. Cancer Immunol Res. 2019;7:841-852 pubmed publisher
DussÃ©aux M, Masse Ranson G, Darche S, Ahodantin J, Li Y, Fiquet O, et al. Viral Load Affects the Immune Response to HBV in Mice With Humanized Immune System and Liver. Gastroenterology. 2017;153:1647-1661.e9 pubmed publisher
Kammerer Jacquet S, Brunot A, Bensalah K, Campillo Gimenez B, Lefort M, Bayat S, et al. Hilar fat infiltration: A new prognostic factor in metastatic clear cell renal cell carcinoma with first-line sunitinib treatment. Urol Oncol. 2017;35:603.e7-603.e14 pubmed publisher
Zhou J, Mahoney K, Giobbie Hurder A, Zhao F, Lee S, Liao X, et al. Soluble PD-L1 as a Biomarker in Malignant Melanoma Treated with Checkpoint Blockade. Cancer Immunol Res. 2017;5:480-492 pubmed publisher
Chevrier S, Levine J, Zanotelli V, Silina K, Schulz D, Bacac M, et al. An Immune Atlas of Clear Cell Renal Cell Carcinoma. Cell. 2017;169:736-749.e18 pubmed publisher
Rebelatto M, Midha A, Mistry A, Sabalos C, Schechter N, Li X, et al. Development of a programmed cell death ligand-1 immunohistochemical assay validated for analysis of non-small cell lung cancer and head and neck squamous cell carcinoma. Diagn Pathol. 2016;11:95 pubmed
Kammerer Jacquet S, Crouzet L, Brunot A, Dagher J, Pladys A, Edeline J, et al. Independent association of PD-L1 expression with noninactivated VHL clear cell renal cell carcinoma-A finding with therapeutic potential. Int J Cancer. 2017;140:142-148 pubmed publisher
Gatalica Z, Bilalovic N, Palazzo J, Bender R, Swensen J, Millis S, et al. Disseminated histiocytoses biomarkers beyond BRAFV600E: frequent expression of PD-L1. Oncotarget. 2015;6:19819-25 pubmed
Mazel M, Jacot W, Pantel K, Bartkowiak K, Topart D, Cayrefourcq L, et al. Frequent expression of PD-L1 on circulating breast cancer cells. Mol Oncol. 2015;9:1773-82 pubmed publisher
Song X, Liu J, Lu Y, Jin H, Huang D. Overexpression of B7-H1 correlates with malignant cell proliferation in pancreatic cancer. Oncol Rep. 2014;31:1191-8 pubmed publisher
Rojas D, Krishnan R. IFN-gamma generates maturation-arrested dendritic cells that induce T cell hyporesponsiveness independent of Foxp3+ T-regulatory cell generation. Immunol Lett. 2010;132:31-7 pubmed publisher

product information

brand :

R&D Systems

master code :

MAB1561

SKU :

MAB1561

product name :

Human PD-L1/B7-H1 Antibody

unit size :

100 ug (also 25 ug)

seo description :

The Human PD-L1/B7-H1 Antibody from R&D Systems is a mouse monoclonal antibody to PD-L1. This antibody reacts with human. The Human PD-L1/B7-H1 Antibody has been validated for the following applications: ELISA Development (Capture),Flow Cytometry,Western Blot,ELISA Detection,Immunohistochemistry,Immunohistochemistry-Paraffin,Immunofluorescence,Immunocytochemistry,CyTOF-ready,Dual RNAscope ISH-IHC Compatible.

target :

PD-L1/B7-H1

category :

Primary Antibodies

buffer :

Lyophilized from a 0.2 ╡m filtered solution in PBS with Trehalose. See Certificate of Analysis for details. *Small pack size (-SP) is supplied either lyophilized or as a 0.2 ╡m filtered solution in PBS.

clonality :

Monoclonal

clone :

130021

concentration :

LYOPH

conjugate :

Unconjugated

dilution :

Flow Cytometry 0.25 ug/10^6 cells, Immunohistochemistry 8-25 ug/mL, CyTOF-ready, Dual RNAscope ISH-IHC 3-25 ug/mL

host :

Mouse

immunogen :

Mouse myeloma cell line NS0-derived recombinant human PD-L1/B7-H1, Phe19-Thr239, Accession # Q9NZQ7

isotype :

IgG1

purity :

Protein A or G purified from hybridoma culture supernatant

species :

Human

specificity :

Detects human PD-L1/B7-H1 in direct ELISAs. In direct ELISAs, no cross-reactivity with recombinant human (rh) B7-1, -2, -H2, -H3, -H3b, -H4, rhPD-L2, recombinant mouse B7-H1, recombinant rat (rr) B7-1, or rrB7-2 is observed.

gene symbol :

CD274

top caption :

Detection of PD-L1/B7-H1 antibody in Jurkat Human Cell Line antibody by Flow Cytometry.

accessionNumbers :

Q9NZQ7

applications :

CyTOF-ready,Dual RNAscope ISH-IHC Compatible,ELISA Development (Capture),Flow Cytometry,Immunohistochemistry,Western Blot,Immunohistochemistry-Paraffin,Immunofluorescence,Immunocytochemistry,ELISA Detection

USD :

489 USD

alt names :

Avelumab, B7-H, B7H1, B7-H1, B7H1PDCD1L1, CD274, CD274 antigenMGC142294, CD274 molecule, PDCD1L1, PDCD1LG1, PDCD1LG1MGC142296, PDL1, PD-L1, PD-L1B7 homolog 1, PDL1PDCD1 ligand 1, programmed cell death 1 ligand 1, Programmed death ligand 1

storage :

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 ░C as supplied. 1 month, 2 to 8 ░C under sterile conditions after reconstitution. 6 months, -20 to -70 ░C under sterile conditions after reconstitution.

more info or order :

R&D Systems product webpage